



Jitty Malik, PhD

Partner

Intellectual Property

Charlotte Office | +1.704.344.3185

jitty.malik@katten.com

Dr. Jitendra "Jitty" Malik has a wide-ranging patent practice, which includes patent litigation, post-grant patent practice before the US Patent and Trademark Office, patent counseling and patent prosecution. With particular experience in the drug approval process under the Hatch-Waxman and Biologics Price Competition and Innovation Acts, he helps clients in developing strategies for marketing drug and biologic/biosimilar products, and challenging patents pursuant to the Hatch-Waxman Act and BPCIA.

Patent counsel informed by scientific knowledge

Jitty's practice encompasses patent litigation, post-grant patent review, opinions, IP due diligence, licensing and prosecution. He is experienced in handling matters in which patents are challenged post grant before the US Patent & Trademark Office, including *inter partes* review and post-grant review process, *ex-parte* reexaminations and reissues.

His scientific knowledge includes chemistry, biochemistry, organometallic chemistry, polymer chemistry, physics and electrochemistry. Prior to law school, Jitty was a project supervisor for a leading chemical materials manufacturer. He has been published many times in scholarly scientific and legal publications and is a frequent speaker on legal matters.

Representative Experience

- Litigation in the US District Court for the District of Delaware involving multiple patents associated with the treatment of early-stage idiopathic Parkinson's disease and moderate-to-severe restless legs syndrome using rotigotine.
- Lead trial counsel in the US District Court for the District of Delaware involving patents associated with a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma using melphalan for injection.
- Lead trial counsel in the US District Court for the District of Delaware involving patents associated with the treatment of patients with metastatic colorectal cancer using regorafenib.

Practices

- Intellectual Property
- Intellectual Property Litigation
- Patent Litigation and Patents
- Pharmaceutical and Life Sciences Litigation

Education

- JD, Wake Forest University School of Law
- PhD, University of Cincinnati, Polymer Science and Engineering
- MBA, University of Cincinnati
- MS, The University of North Carolina at Charlotte, Chemistry
- BS, The University of North Carolina, Chemistry

Bar Admissions

- North Carolina

Community Involvements

- Intellectual Property Owners Association, Pharmaceutical & Biotechnology Issues Committee

Jitty Malik, PhD

Partner

- Litigation in the US District Court for the District of New Jersey involving multiple patents directed to methylnaltrexone bromide formulation for subcutaneous injection.
- Lead trial counsel in the US District Court for the District of New Jersey involving patents associated with the treatment of adults with multiple myeloma using lenalidomide.
- Litigated in the US District Court for the District of Delaware involving five patents directed to a controlled release of budesonide.*
- Litigated in the US District Court for the District of New Jersey involving multiple patents directed to treating schizophrenia, bipolar disorder, depression and autism spectrum disorders with aripiprazole.*
- Litigated in the US District Court for the District of Delaware involving multiple patents directed to treating moderate to severe dementia of the Alzheimer's type with memantine.*
- Litigated in the US District Court for the District of New Jersey involving two patents directed to the reduction of elevated total cholesterol using ezetimibe and simvastatin.*
- Section 505(b)(2) Hatch-Waxman litigation in the US District Court for the District of New Jersey involving two patents directed to an intravenous formulation of acetaminophen.*
- Litigated in the US District Court for the District of New Jersey involving numerous patents associated with the treatment of post-operative inflammation and reduction of ocular pain in patients who have undergone cataract surgery using a bromfenac ophthalmic solution.*
- Represented one of the largest pharmaceutical companies in the world as plaintiff in patent infringement action involving medical foods before the US District Court for the Eastern District of Texas.*
- Represented developer of direct bonding technology for 3D integration as plaintiff in patent infringement action involving image sensors before the US District Court for the Northern District of California.*
- Represented one of the world's largest chemical producers as plaintiff in patent infringement action involving animal health products before the US District Court for the Middle District of North Carolina.*
- Defended developer of cardiovascular treatments in patent infringement action involving medical devices before the US District Court for the Northern District of California.*

Jitty Malik, PhD

Partner

- Defended an integrated textile company in patent infringement action involving fabric technology before the US District Court for the Southern District of New York.*
- Defended industrial valve manufacturer in patent infringement action involving industrial petrochemical equipment before the US District Court for the Central District of California.*
- Represented fiber optics developer as plaintiff in patent infringement action before the US District Court for the Northern District of Georgia.*
- Defended one of the largest petrochemical companies in the Americas in patent infringement action involving systems for petrochemical refining before the US District Court for the Western District of Texas.*
- Represented developer of nutrient-use efficiency technologies as plaintiff in litigation involving patent directed to substances that improve plant growth.*

*Experience prior to Katten

Recognitions

Recognized or listed in the following:

- *ANDA Litigation Intelligence Report*
 - Best Performing ANDA Attorneys Representing Defendants, 2021–2022; Top 1, 2023; Top 50, 2024
 - Most Active ANDA Attorneys Representing Defendants, Top 100, 2021; Top 10, 2023; Top 10, 2024
 - Best Performing ANDA Attorneys Overall (Representing Plaintiffs or Defendants), Top 3, 2023; 2024
 - Most Active ANDA Attorneys Overall (Representing Plaintiffs and Defendants), Top 100, 2021–2023; Top 25, 2024
- *Best Lawyers in America*
 - Litigation – Patent and Patent Law, 2025
- *BTI Client Service All-Stars*
 - 2020
- IAM Patent 1000
 - Recognized Individual, United States, 2023
 - Recognized Individual, North Carolina, 2020–2024
- IPR Intelligence Report

Jitty Malik, PhD

Partner

- Top 100 Best Performing IPR Attorneys Representing Petitioners

News

- Katten Ranked Top Three Firm in ANDA Litigation (September 3, 2024)
- Katten Attorneys Recognized as *Best Lawyers®* and *Best Lawyers: Ones to Watch®* Award Recipients (August 15, 2024)
- Katten Named Intellectual Property Leader in *IAM Patent 1000* (June 5, 2024)
- Another Precedent-Setting Remand from the Federal Circuit Garners Media Attention (April 2, 2024)
- Katten's IP Litigation Team Prevails at Trial, Securing Patent Win for Mylan Pharmaceuticals (March 15, 2024)
- Precedent-Setting Patent Win in Federal Circuit Creates Media Buzz From *Bloomberg Law*, *Reuters*, and More (November 7, 2023)
- Katten Ranked Top Three Firm in Hatch-Waxman Litigation (September 5, 2023)
- Katten IP Practice Lauded in *IAM Patent 1000* (June 29, 2023)
- Fed. Circ. Won't Revive Parkinson's Drug Patent | *Law360* (April 12, 2023)
- Katten Intellectual Property Team Secures Significant Victory for Apotex in Hatch-Waxman Litigation (November 1, 2022)
- Katten Ranks Among Top Three Most Active Law Firms in ANDA Litigation (August 22, 2022)
- Katten Lauded in *IAM Patent 1000 2022* (June 29, 2022)
- [Report: The Best Hatch-Waxman Law Firms of 2021 | IP Watchdog](#) (October 18, 2021)
- Katten Ranked in Top Five Most Active Law Firms for ANDA Litigation (August 23, 2021)
- Katten Attorneys Named Leaders in Patent Law by *IAM Patent 1000* (July 6, 2021)
- Katten Client Mylan Wins Patent Infringement Case Regarding Parkinson's Drug Treatment (June 11, 2021)
- Katten Partners Praised for Outstanding Client Service (December 10, 2020)
- Katten Named Among Top Three Best Performing Law Firms for ANDA Litigation (August 19, 2020)

Jitty Malik, PhD

Partner

- Katten Attorneys Named Leaders in Patent Law by *IAM Patent 1000* (June 22, 2020)
- [Generics' 2nd Challenge To Acne Drug IP Succeeds At PTAB](#) (June 2, 2020)
- [MDL Won't Stop PTAB From Reviewing Merck Diabetes Patent](#) (May 13, 2020)
- Katten Intellectual Property Partner Featured in Patent Industry Report (August 29, 2019)
- Katten Draws Top IP Litigation Talent with Broad Pharma Experience (May 7, 2018)

Publications

- *USPTO Post-Grant Trials Handbook* (2016)
- A Second Bite of the Apple? Potential to Expand an Invalidity Argument in an IPR is Not Precluded by Joinder (May 2015)

Presentations and Events

- The Defend Trade Secrets Act (June 21, 2016) | *Co-presenter*
- Biotechnology Industry Organization (BIO) (April 17, 2015) | *Moderator* | *Recent Developments in IPR and Their Effect on the Life Sciences* | *Bio IP Counsels Committee Conference*